Related Experiment Video
Updated: May 12, 2026
09:12
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
A RTK-based functional RNAi screen reveals determinants of PTX-3 expression
Hua Liu1, Xin-Kai Qu, Fang Yuan
1Department of Cardiology, Shanghai Chest Hospital affiliated to Shanghai JiaoTong University, Shanghai, China.
International Journal of Clinical and Experimental Pathology
|April 11, 2013
Summary
Receptor tyrosine kinases (RTKs) regulate PTX-3 expression, a key factor in atherosclerosis. Inhibiting RTKs may impact cardiovascular health, especially in cancer patients with atherosclerosis risk.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Oncology
Background:
- PTX-3 is a crucial protector against atherosclerosis.
- Receptor tyrosine kinases (RTKs) play roles in cellular signaling pathways.
- Understanding RTK involvement in PTX-3 regulation is vital for cardiovascular health.
Purpose of the Study:
- To investigate the role of RTKs in regulating PTX-3 expression.
- To identify specific RTKs involved in PTX-3 modulation.
- To explore potential cardiotoxicity of RTK inhibitors in atherosclerosis.
Main Methods:
- Utilized shRNA lentiviral vector library targeting RTKs in U937 cells.
- Assessed PTX-3 expression via ELISA and Western blotting.
- Analyzed downstream signaling pathways including AKT and p38.
Main Results:
- Knockdown of ERBB2/3, EPHA7, FGFR3, and RET impaired PTX-3 expression.
- AKT inhibition reduced PTX-3 expression, indicating its downstream role.
- FGFR3 inhibition via anti-cancer drugs decreased p38 activity and PTX-3 levels.
Conclusions:
- RTKs are key regulators of PTX-3 expression.
- RTK inhibitors may pose a cardiotoxicity risk in patients with atherosclerosis.
- This highlights the need for careful consideration of RTK inhibitor use in at-risk populations.
